News

11 April 2017: Vantia Therapeutics Completes Enrollment in the EQUINOC® Study

Vantia Therapeutics Completes Enrollment in the EQUINOC® Study, a Pivotal Study with Fedovapagon for the Treatment of Nocturia in Men with Benign Prostatic Hyperplasia.

9 May 2016: Vantia Therapeutics Publishes NocTIMe, at the AUA Meeting in San Diego, 2016

Vantia Therapeutics Publishes The Nocturia Patient Reported Outcome Instrument, Nocturia Treatment Impact Measure, NocTIMe, at the American Urological Association Meeting in San Diego, 2016.

21 March 2016: Vantia Therapeutics Initiates the EQUINOC® Study

Vantia Therapeutics Publishes The Nocturia Patient Reported Outcome Instrument, Nocturia Treatment Impact Measure, NocTIMe, at the American Urological Association Meeting in San Diego, 2016.